Association of Dexmedetomidine With New-Onset Atrial Fibrillation in Patients With Critical Illness

Overview

Journal JAMA Netw Open

Publisher American Medical Association

Specialty General Medicine

Date 2023 Apr 25

PMID 37097632

Authors

Myung Jin Song

Yeonhoon Jang

Ji Hyun Lee

Joo Heung Yoon

Dong Jung Kim

Se Young Jung

Sung Yoon Lim

Affiliations

Soon will be listed here.

Abstract

Importance: Dexmedetomidine is a widely used sedative in the intensive care unit (ICU) and has unique properties that may be associated with reduced occurrence of new-onset atrial fibrillation (NOAF).

Objective: To investigate whether the use of dexmedetomidine is associated with the incidence of NOAF in patients with critical illness.

Design, Setting, And Participants: This propensity score-matched cohort study was conducted using the Medical Information Mart for Intensive Care-IV database, which includes records of patients admitted to the ICU at Beth Israel Deaconess Medical Center in Boston dating 2008 through 2019. Included patients were those aged 18 years or older and hospitalized in the ICU. Data were analyzed from March through May 2022.

Exposure: Patients were divided into 2 groups according to dexmedetomidine exposure: those who received dexmedetomidine within 48 hours after ICU admission (dexmedetomidine group) and those who never received dexmedetomidine (no dexmedetomidine group).

Main Outcomes And Measures: The primary outcome was the occurrence of NOAF within 7 days of ICU admission, as defined by the nurse-recorded rhythm status. Secondary outcomes were ICU length of stay, hospital length of stay, and in-hospital mortality.

Results: This study included 22 237 patients before matching (mean [SD] age, 65.9 [16.7] years; 12 350 male patients [55.5%]). After 1:3 propensity score matching, the cohort included 8015 patients (mean [SD] age, 61.0 [17.1] years; 5240 males [65.4%]), among whom 2106 and 5909 patients were in the dexmedetomidine and no dexmedetomidine groups, respectively. Use of dexmedetomidine was associated with a decreased risk of NOAF (371 patients [17.6%] vs 1323 patients [22.4%]; hazard ratio, 0.80; 95% CI, 0.71-0.90). Although patients in the dexmedetomidine group had longer median (IQR) length of stays in the ICU (4.0 [2.7-6.9] days vs 3.5 [2.5-5.9] days; P < .001) and hospital (10.0 [6.6-16.3] days vs 8.8 [5.9-14.0] days; P < .001), dexmedetomidine was associated with decreased risk of in-hospital mortality (132 deaths [6.3%] vs 758 deaths [12.8%]; hazard ratio, 0.43; 95% CI, 0.36-0.52).

Conclusions And Relevance: This study found that dexmedetomidine was associated with decreased risk of NOAF in patients with critical illness, suggesting that it may be necessary and warranted to evaluate this association in future clinical trials.

Citing Articles

Effect of dexmedetomidine on postoperative delirium in patients undergoing type A aortic dissection surgery: a prospective cohort study.

Yu Y, Wang Y, Zhu X, Li L, Wang D, Wang Y J Thorac Dis. 2025; 17(1):161-173.

PMID: 39975717 PMC: 11833563. DOI: 10.21037/jtd-24-1219.

Dexmedetomidine administration is associated with improved outcomes in critically ill patients with acute myocardial infarction partly through its anti-inflammatory activity.

Liu Y, Chen Q, Hu T, Deng C, Huang J Front Pharmacol. 2024; 15:1428210.

PMID: 39239649 PMC: 11375293. DOI: 10.3389/fphar.2024.1428210.

Mapping Theme Trends and Research Frontiers in Dexmedetomidine Over Past Decade: A Bibliometric Analysis.

Chen Z, Zuo Z, Song X, Zuo Y, Zhang L, Ye Y Drug Des Devel Ther. 2024; 18:3043-3061.

PMID: 39050803 PMC: 11268573. DOI: 10.2147/DDDT.S459431.

Dexmedetomidine as an effective alternative tool for heart rate control in atrial fibrillation during general anesthesia-A case report.

Heo M, Cho M, Lee S, Kim K Saudi J Anaesth. 2024; 18(2):299-301.

PMID: 38654877 PMC: 11033889. DOI: 10.4103/sja.sja_918_23.

References

Wetterslev M, Haase N, Hassager C, Belley-Cote E, McIntyre W, An Y . New-onset atrial fibrillation in adult critically ill patients: a scoping review. Intensive Care Med. 2019; 45(7):928-938. DOI: 10.1007/s00134-019-05633-x. View

Turan A, Duncan A, Leung S, Karimi N, Fang J, Mao G . Dexmedetomidine for reduction of atrial fibrillation and delirium after cardiac surgery (DECADE): a randomised placebo-controlled trial. Lancet. 2020; 396(10245):177-185. DOI: 10.1016/S0140-6736(20)30631-0. View

Moller M, Alhazzani W, Lewis K, Belley-Cote E, Granholm A, Centofanti J . Use of dexmedetomidine for sedation in mechanically ventilated adult ICU patients: a rapid practice guideline. Intensive Care Med. 2022; 48(7):801-810. DOI: 10.1007/s00134-022-06660-x. View

Austin P . Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009; 28(25):3083-107. PMC: 3472075. DOI: 10.1002/sim.3697. View

Nishina K, Akamatsu H, Mikawa K, Shiga M, Maekawa N, Obara H . The effects of clonidine and dexmedetomidine on human neutrophil functions. Anesth Analg. 1999; 88(2):452-8. DOI: 10.1097/00000539-199902000-00042. View

Offerhaus J, Joosten L, van Smeden M, Linschoten M, Bleijendaal H, Tieleman R . Sex- and age specific association of new-onset atrial fibrillation with in-hospital mortality in hospitalised COVID-19 patients. Int J Cardiol Heart Vasc. 2022; 39:100970. PMC: 8813563. DOI: 10.1016/j.ijcha.2022.100970. View

Zi J, Fan Y, Dong C, Zhao Y, Li D, Tan Q . Anxiety Administrated by Dexmedetomidine to Prevent New-Onset of Postoperative Atrial Fibrillation in Patients Undergoing Off-Pump Coronary Artery Bypass Graft. Int Heart J. 2020; 61(2):263-272. DOI: 10.1536/ihj.19-132. View

Bosch N, Cimini J, Walkey A . Atrial Fibrillation in the ICU. Chest. 2018; 154(6):1424-1434. PMC: 6335260. DOI: 10.1016/j.chest.2018.03.040. View

Riker R, Shehabi Y, Bokesch P, Ceraso D, Wisemandle W, Koura F . Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA. 2009; 301(5):489-99. DOI: 10.1001/jama.2009.56. View

10.

Santhakumaran S, Gordon A, Prevost A, OKane C, McAuley D, Shankar-Hari M . Heterogeneity of treatment effect by baseline risk of mortality in critically ill patients: re-analysis of three recent sepsis and ARDS randomised controlled trials. Crit Care. 2019; 23(1):156. PMC: 6500045. DOI: 10.1186/s13054-019-2446-1. View

11.

Keating G . Dexmedetomidine: A Review of Its Use for Sedation in the Intensive Care Setting. Drugs. 2015; 75(10):1119-30. DOI: 10.1007/s40265-015-0419-5. View

12.

Fernando S, Mathew R, Hibbert B, Rochwerg B, Munshi L, Walkey A . New-onset atrial fibrillation and associated outcomes and resource use among critically ill adults-a multicenter retrospective cohort study. Crit Care. 2020; 24(1):15. PMC: 6958729. DOI: 10.1186/s13054-020-2730-0. View

13.

Echahidi N, Pibarot P, OHara G, Mathieu P . Mechanisms, prevention, and treatment of atrial fibrillation after cardiac surgery. J Am Coll Cardiol. 2008; 51(8):793-801. DOI: 10.1016/j.jacc.2007.10.043. View

14.

Annane D, Sebille V, Duboc D, Le Heuzey J, Sadoul N, Bouvier E . Incidence and prognosis of sustained arrhythmias in critically ill patients. Am J Respir Crit Care Med. 2008; 178(1):20-5. DOI: 10.1164/rccm.200701-031OC. View

15.

Alonso A, Agarwal S, Soliman E, Ambrose M, Chamberlain A, Prineas R . Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2009; 158(1):111-7. PMC: 2720573. DOI: 10.1016/j.ahj.2009.05.010. View

16.

Jacobs M, Loef B, Reidinga A, Postma M, van Hulst M, Tieleman R . Incidence, treatment and mortality of new-onset atrial fibrillation patients at the intensive care unit. Open Heart. 2020; 7(1):e001226. PMC: 7254104. DOI: 10.1136/openhrt-2019-001226. View

17.

Knotzer H, Mayr A, Ulmer H, Lederer W, Schobersberger W, Mutz N . Tachyarrhythmias in a surgical intensive care unit: a case-controlled epidemiologic study. Intensive Care Med. 2000; 26(7):908-14. DOI: 10.1007/s001340051280. View

18.

Ebert T, Hall J, BARNEY J, Uhrich T, Colinco M . The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology. 2000; 93(2):382-94. DOI: 10.1097/00000542-200008000-00016. View

19.

Venn R, Hell J, Grounds R . Respiratory effects of dexmedetomidine in the surgical patient requiring intensive care. Crit Care. 2000; 4(5):302-8. PMC: 29047. DOI: 10.1186/cc712. View

20.

Ding E, Albuquerque D, Winter M, Binici S, Piche J, Bashar S . Novel Method of Atrial Fibrillation Case Identification and Burden Estimation Using the MIMIC-III Electronic Health Data Set. J Intensive Care Med. 2019; 34(10):851-857. PMC: 7050656. DOI: 10.1177/0885066619866172. View